KR20190074515A - Hemostatic gel composition for animal - Google Patents

Abstract

The present invention relates to a gel-type hemostatic composition for animal. In particular, provided is a technique for preparing a gel-type hemostat for animal which comprises: at least one hemostatic component selected from the group consisting of ferric sulfate, ferric subsulfate, aluminium sulfate, copper sulfate, aluminium chloride, zinc chloride, silver nitrate, and a mixture thereof; a solvent provided to be mixed with the hemostatic component; at least one first viscosity-regulating component selected from the group consisting of cellulose, cellulose derivatives, and a mixture thereof; and a second viscosity-regulating component to be mixed with the first viscosity-regulating component in order to control viscosity. The gel-type hemostatic composition for animal according to the present invention may solve the problem associated with clay minerals.

Description

HEMOSTATIC GEL COMPOSITION FOR ANIMAL [0002]

The present invention relates to a hemostatic composition for a gel-type animal.

In recent years, home-based pets can be easily found in the vicinity, and a service industry such as a pet beauty business is also on the rise. Among the people who raise dogs, dogs, etc., it is often the dogs or cats who care for the toes or the beaks of the birds themselves. If you are looking for a pet beauty shop as well as if you care for your dog's claws or bird's beaks, you may accidentally damage your pet's blood vessels during the course of the shine, There was a risk of interruption or infection of the wound site.

In such a case, it is necessary to improve the quality of life of the pet through rapid treatment, and in particular, the outflow of excess blood outside the blood vessel can be directly linked to the life of the animal, so hemostasis has to proceed as fast as possible.

Regarding the hemostatic agent technology developed in the past, Korean Patent Registration No. 10-1330011 discloses a technique for a hemostatic agent including diatomaceous earth and silica.

However, hemostatic agents using clay minerals such as silica, bentonite, and diatomaceous earth have the possibility of secondary pain caused by adsorption heat generated when the clay mineral component absorbs blood.

In addition, since general clay minerals are insoluble in water, they are not well dispersed when mixed with water, which may cause separation of layers, resulting in poor formulation stability and difficulty in uniformly dispersing hemostatic components in the hemostatic composition. However, it was technically difficult to develop a gel-type hemostatic agent which is easy to use.

SUMMARY OF THE INVENTION The present invention has been made to solve the above problems, and it is an object of the present invention to provide a technique for manufacturing a gel type animal hemostatic agent which improves the problems caused by clay minerals and has an excellent hemostatic function and is easy to use.

The present invention has been made in view of the above problems, and it is an object of the present invention to provide an apparatus and method for controlling the same.

In order to achieve the above object, the present invention provides a hemostatic composition for a gel type animal, comprising ferric sulfate, ferric subsulfate, aluminum sulfate, copper sulfate, aluminum chloride aluminum chloride, zinc chloride, silver nitrate, and a mixture thereof; A solvent adapted to be mixed with the hemostatic component; A first component for controlling viscosity, which is at least one selected from the group consisting of cellulose, cellulose derivatives, and mixtures thereof; And a viscosity-controlling second component that is mixed with the viscosity-controlling first component to control the viscosity.

In the hemostatic composition for a gel-type animal, the hemostatic component is 20 to 40 parts by weight, the solvent is 50 to 80 parts by weight, the viscosity-controlling first component is 4 to 7 parts by weight per 66 parts by weight of the solvent, The second controlling component may be provided in an amount of 6 to 9 parts by weight per 66 parts by weight of the solvent.

The cellulose derivative may be at least one of carboxymethyl cellulose and hydroxyethyl cellulose.

The second component for controlling viscosity may be at least one selected from the group consisting of butylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, and mixtures thereof. .

The hemostatic composition for a gel type animal further comprises 0.1 to 10 parts by weight of an antibacterial agent, wherein the antibacterial agent is selected from the group consisting of povidone iodine, chloroxyrenol, lactoferrin, lysozyme, At least one selected from the group consisting of chitosan, nisin, and polylysine.

In addition, the viscosity of the gel-type animal hemostatic composition can be applied in the range of 1,000 to 30,000 cPs.

The solution of the above-mentioned problems is merely illustrative and should not be construed as limiting the present invention. In addition to the exemplary embodiments described above, there may be additional embodiments described in the drawings and the detailed description of the invention.

As described above, according to the present invention, since the clay mineral is not used, it is possible to prevent the pain caused by the clay mineral component when the hemostatic composition is absorbed by blood.

In addition, it is easy to control the viscosity of the hemostatic composition through the first component and the second component for viscosity control within the range of 1,000 to 30,000 cPs, which is suitable for the preparation of a gel-type formulation. Furthermore, the present invention uses the biocompatible polymer as the first component for controlling viscosity, and thus has excellent stability in the body.

In addition, since the first component for viscosity control is uniformly mixed with water and the dispersibility is excellent, layer separation does not occur. Therefore, the present invention is not only superior in formulation stability, It has excellent effect.

In addition, since the present invention maintains a gel form at room temperature, it is convenient to apply the hemostatic agent to a bleeding site in comparison with a liquid or powder type hemostatic agent, and the convenience of use is improved.

The effects of the present invention are not limited to the effects mentioned above, and other effects not mentioned can be clearly understood by those skilled in the art from the description of the claims.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph of an experimental method for confirming the hemostatic effect of various embodiments of the present invention. FIG.

The preferred embodiments of the present invention will be described in more detail with reference to the accompanying drawings, in which the technical parts already known will be omitted or compressed for simplicity of explanation.

In the following embodiments, the terms first, second, and the like are used for the purpose of distinguishing one element from another element, not the limitative meaning.

In the following examples, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise.

In the following embodiments, terms such as inclusive or having mean that a feature or element described in the specification is present, and do not exclude the possibility that one or more other features or elements are added in advance.

The term "about," as used in reference to figures throughout the specification, when used in the figures or in close proximity to the numerical values when both manufacturing and material tolerances inherent in the stated sense are presented, Absolute numbers are used to prevent unauthorized exploitation by unauthorized intruders of the mentioned disclosure. In certain embodiments, the term " about "means a standard deviation within 1, 2, 3 or 4. In another embodiment, the term "about" is used to refer to any of the following: 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% Respectively.

The hemostatic composition for a gel type animal according to an embodiment of the present invention may include a hemostatic component, a solvent, a first component for viscosity control, and a second component for viscosity control.

In one embodiment, the hemostatic component is a substance that coagulates the blood formed at the bleeding site, and may be applied in an amount of 20 to 40 parts by weight. As a specific example, the hemostatic component may be provided in an amount of about 20 parts by weight, about 25 parts by weight, about 30 parts by weight, about 35 parts by weight or about 40 parts by weight. In addition, the content of the hemostatic component may be in the range of one or more of the above values and one or less of the above values.

For example, the range of hemostatic components may be from about 20 parts by weight to about 25 parts by weight, from about 25 parts by weight to about 30 parts by weight, from about 30 parts by weight to about 35 parts by weight, from about 35 parts by weight to about 40 parts by weight, May range from about 20 parts by weight to about 40 parts by weight. When the hemostatic component according to one embodiment is mixed with the other components of the hemostatic composition in the above range, it is easy to prepare the formulation of the hemostatic composition in gel form.

If the hemostatic component is less than 20 parts by weight, the hemostatic function may be lowered and the hemostasis of the bleeding part may be restricted. If the hemostatic component exceeds 40 parts by weight, the manufacturing cost is increased and the hemostatic component It is difficult to control the mixing ratio of the first component for controlling viscosity and the second component for controlling viscosity, and it is difficult to prepare the formulation of the hemostatic composition in gel form. Therefore, the content of hemostatic component is preferably within the above-mentioned range.

In one embodiment, the hemostatic component is selected from the group consisting of ferric sulfate, ferric subsulfate, aluminum sulfate, copper sulfate, aluminum chloride, zinc chloride, (silver nitrate), and a mixture thereof.

In one embodiment, the solvent may be mixed with a hemostatic component, a viscosity control ingredient, and a viscosity control ingredient. In addition, the solvent may be applied in an amount of 50 to 80 parts by weight as an aqueous solvent type such as water or distilled water. As a specific example, the content of the solvent may be about 50 parts by weight, about 55 parts by weight, about 60 parts by weight, about 65 parts by weight, about 70 parts by weight, about 75 parts by weight or about 80 parts by weight. And, the content of the solvent may be in the range of at least one of the above values and one or less of the above values.

For example, the solvent may range from about 50 parts by weight to about 55 parts by weight, from about 55 parts by weight to about 60 parts by weight, from about 60 parts by weight to about 65 parts by weight, from about 65 parts by weight to about 70 parts by weight, From about 70 parts by weight to about 75 parts by weight, from about 75 parts by weight to about 80 parts by weight, or from about 50 parts by weight to about 80 parts by weight. The solvent according to one embodiment can maintain the formulation of the composition for hemostasis in the gel in the above-mentioned range, and the viscosity of the hemostatic composition can be adjusted so that the hemostatic performance and convenience of use of the hemostatic composition are maintained at a good level.

If the amount of the solvent is less than 50 parts by weight, the viscosity of the hemostatic composition increases excessively, which may cause an inconvenience in using the hemostatic composition in the process of squeezing the hemostatic composition from the tube vessel. There is a fear that the blood-circulating ability can not be sufficiently lowered.

When the solvent is more than 80 parts by weight, as the formulation of the hemostatic composition becomes closer to the liquid phase, the hemostatic composition flows immediately after the hemostatic composition is applied to the hemostatic site, resulting in lowered hemostatic effect and inconvenient use. Is preferably applied within the above-mentioned range.

In one embodiment, the first component for viscosity control can adjust the viscosity of the hemostatic composition so that the hemostatic composition can maintain a gel form at room temperature, and can be applied with 4-7 parts by weight per 66 parts by weight of solvent. As a specific example, the content of the first viscosity controlling component may be provided in about 4 parts by weight, about 5 parts by weight, about 6 parts by weight, or about 7 parts by weight, based on 66 parts by weight of the solvent. And, the content of the first component for controlling viscosity may be in the range of at least one of the above values and one or less of the above values.

For example, the content range of the first component for viscosity control may be from about 4 parts by weight to about 5 parts by weight, from about 5 parts by weight to about 6 parts by weight, from about 6 parts by weight to about 7 parts by weight, from about 4 parts by weight to about 6 Parts by weight, about 5 parts by weight to about 7 parts by weight, or about 4 parts by weight to about 7 parts by weight. The first component for controlling viscosity according to one embodiment can formulate the composition of the composition for hemostasis in the above-mentioned range in a gel form, and can maintain excellent hemostatic performance.

If the viscosity-controlling first component is less than 4 parts by weight based on 66 parts by weight of the solvent, rebleeding may occur immediately after the drop in hemostatic capacity or hemostasis. If the viscosity-controlling first component exceeds 7 parts by weight It is difficult to expect a hemostatic effect because the blood and the hemostatic composition are not properly mixed due to excessive viscosity, so that the content of the first component for viscosity control is preferably within the above-mentioned range.

The first component for viscosity control that may be used in one embodiment is a biocompatible polymer and may be provided in at least one selected from the group consisting of cellulose, cellulose derivatives, and mixtures thereof.

Here, the cellulose derivative may be applied to at least one of carboxymethyl cellulose and hydroxyethyl cellulose, but is not limited thereto, and known cellulose derivatives other than the above-mentioned types may be used.

Since the first component for controlling viscosity according to one embodiment is a water-soluble polymer, the solubility of the first component for viscosity control is very high with respect to an aqueous solvent. When the first component for viscosity control is mixed with an aqueous solvent, the first component can be uniformly dispersed in the solvent.

In one embodiment, the viscosity-controlling second component may be mixed with the viscosity-controlling first component to adjust the viscosity of the entire hemostatic composition to an appropriate level and the viscosity-controlling second component may be provided at 6 to 9 parts by weight per 66 parts by weight of solvent .

As a specific example, the content of the second viscosity controlling component may be about 6 parts by weight, about 7 parts by weight, about 8 parts by weight or about 9 parts by weight, based on 66 parts by weight of the solvent. Further, the content of the second component for controlling viscosity may be in the range of at least one of the above-mentioned values and not more than one of the aforementioned values.

For example, the content range of the second viscosity controlling component may be from about 6 parts to about 7 parts, from about 7 parts to about 8 parts, from about 8 parts to about 9 parts, from about 6 parts to about 8 parts, From about 7 parts by weight to about 9 parts by weight, or from about 6 parts by weight to about 9 parts by weight. The second component for viscosity control according to one embodiment is easy to adjust the viscosity of the whole herbal composition in the above range to a level suitable for use.

If the viscosity-controlling second component is less than 6 parts by weight based on 66 parts by weight of the solvent, the viscosity becomes too high, and excessive pressure is required in the process of squeezing the hemostatic composition from the tube container, The blood and the hemostatic composition can not be sufficiently mixed and the hemostatic capacity may be lowered.

When the viscosity-controlling second component is more than 9 parts by weight based on 66 parts by weight of the solvent, the viscosity of the composition becomes too low, so that the formulation of the hemostatic composition becomes close to the liquid phase. After the hemostatic composition is applied to the bleeding site, There is a problem that the hemostatic effect is lowered and it is inconvenient to use. Therefore, the content of the second component for controlling viscosity is preferably within the above-mentioned range.

As a second component for controlling viscosity which can be used in one embodiment, there may be mentioned a group consisting of butylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, May be used.

Meanwhile, the hemostatic composition for a gel-type animal according to one embodiment may further include 0.1 to 10 parts by weight of an antibacterial agent. As a specific example, the antimicrobial agent may be present in an amount of about 0.1 parts by weight, about 0.5 parts by weight, about 1 part by weight, about 2 parts by weight, about 3 parts by weight, about 4 parts by weight, about 5 parts by weight, about 6 parts by weight, About 8 parts by weight, about 9 parts by weight, or about 10 parts by weight. In addition, the content of the antimicrobial agent may be in a range of at least one of the above values and one or less of the above values.

For example, the antimicrobial agent may be present in an amount ranging from about 0.1 parts to about 1 part, from about 0.5 parts to about 2 parts, from about 1 part to about 4 parts, from about 4 parts to about 7 parts, 7 parts by weight to about 10 parts by weight, or about 0.1 parts by weight to about 10 parts by weight. The antimicrobial agent according to one embodiment may maintain an excellent level of antimicrobial activity within the above range and may be mixed at an appropriate ratio with other components contained in the hemostatic composition.

If the amount of the antibacterial agent is less than 0.1 part by weight, the antibacterial effect is deteriorated. If the antibacterial agent is more than 10 parts by weight, it is difficult to appropriately adjust the content of the hemostatic component, the viscosity controlling first component, It is difficult to form the composition with a viscosity of 1,000 to 30,000 cPs. Therefore, the content of the antimicrobial agent is preferably within the above-mentioned range.

In one embodiment, the antimicrobial agents that can be used include povidone iodine, chloroxyrenol, lactoferrin, lysozyme, chitosan, nisin, and polylysine. . However, the type of antimicrobial agent is not limited to the above-mentioned examples, and it is also possible to use other types of antimicrobial agents known in the art.

The viscosity of the hemostatic composition for a gel type animal according to one embodiment may be in the range of 1,000 to 30,000 cPs (centi poise). Here, the viscosity range of 1,000 to 30,000 cPs means a value measured with a Brookfield viscometer (25 ° C, spindle 64, 50 rpm).

In one embodiment, when the viscosity of the whole hemostatic composition is less than 1,000 cPs, the composition of the composition becomes close to the liquid phase, so that the hemostatic composition immediately flows after the hemostatic composition is applied to the hemostatic site, When the viscosity exceeds 30,000 cPs, the viscosity excessively increases, and excessive pressure is required when squeezing the hemostatic composition from the tube container, which may cause inconvenience in use, and the hemostatic composition may not be sufficiently mixed with the blood and the hemostatic composition. It is preferable to adjust the content of each sex component of the gel-type animal hemostatic composition so that the viscosity of the whole hemostatic composition is formed within the above-mentioned range.

Hereinafter, the present invention will be described in more detail with reference to specific production examples and experimental examples. The following Preparation Examples and Experimental Examples are merely examples for helping understanding of the present invention, and thus the scope of the present invention is not limited thereto or limited.

Preparation of hemostatic composition for gel type animal

Preparation Examples 1 to 4, Comparative Examples 1 to 3, Basic Iron Sulfate, Preparation Example 5: Iron Sulfate, Production Example 6: Sulfuric Acid, Production Example 7: Copper Sulfate, Production Example 8: (Water), the first component for viscosity control (Production Examples 1 to 4, Comparative Examples 1 to 3 are hydroxyethylcellulose, Production Example 5 is cellulose acetate, , Production Example 6 is carboxymethylcellulose, Production Examples 7 to 10 are hydroxyethylcellulose), viscosity control second components (Production Examples 1 to 4, Comparative Examples 1 to 3 are butylene glycol, Production Example 5 is propylene glycol, (Preparation Example 6 is polyethylene glycol, Production Example 7 is polypropylene glycol, Production Examples 8 to 10 are butylene glycol) and antibacterial agents (Production Examples 1 to 4, Comparative Examples 1 to 3 are chitosan, Production Example 5 is povidone iodine, Production Example 6 is chlorooxyphenol, Production Example 7 is lactoferrin, Production Example 8 is lysozyme, Production Example 9 is Nysein, (10) was mixed with polylactic acid to prepare an animal hemostatic composition. In Table 1, the unit of each value except for the viscosity (cPs) is grams. The viscosity at 25 DEG C (spindle 64, 60 rpm) was measured using a Brookfield viscometer, and the results are shown in Table 1 below.

ingredient Production Example 1 Production Example 2 Production Example 3 Production Example 4 Production Example 5 Production Example 6 Production Example 7 Production Example 8 Production Example 9 Production Example 10 Comparative Example 1 Comparative Example 2 Comparative Example 3 A 20 20 20 20 20 20 20 20 20 20 20 20 20 B 4 5 6 7 6 6 6 6 6 6 2 3 8 C 9 8 7 6 7 7 7 7 7 7 11 10 5 D One One One One One One One One One One One One One E 66 66 66 66 66 66 66 66 66 66 66 66 66 Viscosity 8,640 12,360 15,640 28,800 14,480 18,800 16,840 20,840 20,840 20,840 240 840 32,220

In Table 1, A represents a hemostatic component, B represents a first component for viscosity control, C represents a second component for viscosity control, D represents an antimicrobial agent, E represents a solvent

On the other hand, a mixture of a hemostatic component (basic ferrous sulfate), a solvent (water), a first component for controlling viscosity (hydroxyethyl cellulose), a second component for viscosity control (butylene glycol) and an antibacterial agent (chitosan) , And the unit of each numerical value except for the viscosity (cPs) in the following Table 2 is grams. The viscosity at 25 DEG C (spindle 64, 60 rpm) was measured using a Brookfield viscometer, and the results are shown in Table 2 below.

ingredient Production Example 11 Production Example 12 Production Example 13 Production Example 14 Production Example 15 Production Example 16 Comparative Example 4 A 20 20 20 20 20 20 20 B 6 6 6 6 6 6 6 C 7 7 7 7 7 7 7 D 0.1 0.5 One 2 5 10 0 E 66.9 66.5 66 65 62 57 67 Viscosity 27,240 28,000 28,800 28,980 29,120 29,900 27,120

In Table 2, A represents a hemostatic component, B represents a first component for viscosity control, C represents a second component for viscosity control, D represents an antimicrobial agent, E represents a solvent

Test and evaluation method of hemostatic composition for gel type animal

1. In vivo hemostatic test by viscosity

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph of an experimental method for confirming the hemostatic effect of various embodiments of the present invention. FIG. Referring to FIG. 1, the hemostatic functions of the respective production examples and comparative examples were evaluated in the order of the following a) to e), and the evaluation results are shown in Table 3 below.

a) Expose femoral blood vessels of SD-rats.

b) Use 23G (gauge) injection needle to stab the blood vessel directly.

c) Induce bleeding.

d) Applied to the bleeding site for each sample of the preparation example and the comparative example.

e) Check whether there is hemostasis immediately or not. If the bleeding occurred within 5 seconds, it was evaluated as immediate bleeding. The hemostasis was assessed by observing rebleeding for 20 minutes after completion of hemostasis.

ingredient Production Example 1 Production Example 2 Production Example 3 Production Example 4 Production Example 5 Production Example 6 Production Example 7 Production Example 8 Production Example 9 Production Example 10 Comparative Example 1 Comparative Example 2 Comparative Example 3 Viscosity 8,640 12,360 15,640 28,800 14,480 18,800 16,840 20,840 20,840 20,840 240 840 32,220 Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis Immediate hemostasis After 3 minutes hemostasis After 3 minutes hemostasis Not bleeding Rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding No rebleeding Immediate rebleeding Immediate rebleeding Not bleeding

As shown in Table 3, when the viscosity of the hemostatic composition is in the range of 1,000 to 30,000 cPs, it can be confirmed that the hemostasis is sufficiently completed. However, when the viscosity is less than 1,000 cPs, , And the hemostatic effect was low. In addition, when the viscosity exceeds 30,000 cPs, it is not only difficult to squeeze the sample, but also it can be confirmed that the blood and the sample are not mixed well and the hemostatic effect is not exhibited.

Further, the results of Table 3 confirm that when the total composition is 100 parts by weight, the first component for viscosity control and the second component for viscosity control are optimal within the specified range based on 66 parts by weight of distilled water In Comparative Examples 1 to 3, which are less than or equal to the above range, the hemostatic ability is immediately lowered or rebleeding occurs. Immediate rebleeding in Table 3 means rebleeding after 10 to 15 seconds from the time of the bleeding.

2. Antimicrobial activity

In order to confirm the antibacterial activity of Production Examples 11 to 16 and Comparative Example 4, the antibacterial activity was tested by the following method.

a) Staphylococcus aureus ATCC 6538 and Escherichia coil ATCC 25922 are prepared.

b) Shake the test bacteria at 37 ° C for 24 hours and measure the number of bacteria. (120 times / minute of shaking)

c) Measure and compare the number of bacteria measured and the number of control samples after incubation for 24 hours.

d) Decrease rate (%) = [(Mb - Mc) / Mb] X 100 is calculated and recorded.

Ma: initial number of bacteria

Mb: the number of the control sample after incubation for 24 hours

Mc: Bacterium of test sample after incubation for 24 hours

2-1. Results of antibacterial experiments

1) Strain 1: Staphylococcus aureus ATCC 6538

2) Strain 2: Escherichia coil ATCC 25922

From the results of the antibacterial activity tests shown in Tables 4 and 5, it can be confirmed that when the content of the antibacterial agent was 0.1 parts by weight or more, the antibacterial activity was shown to be 99.9%. When the antimicrobial agent is used in an amount of more than 10 parts by weight, the viscosity of the whole hemostatic composition is greatly increased due to the mixing ratio with the hemostatic component, the viscosity-controlling first component, the viscosity-controlling second component and the solvent, It was difficult to prepare a hemostatic composition equipped with a hemostatic agent.

As a result, according to various embodiments of the present invention, since the clay mineral is not used in the present invention, it is possible to prevent the pain caused by the clay mineral component when the hemostatic composition is absorbed by blood.

The present invention also facilitates adjusting the viscosity of the hemostatic composition through a first component and a second component for controlling viscosity to a level suitable for preparing a gel-type formulation. Furthermore, the present invention uses the biocompatible polymer as the first component for controlling viscosity, and thus has excellent stability in the body.

In addition, since the first component for viscosity control is uniformly mixed with water and the dispersibility is excellent, layer separation does not occur. Therefore, the present invention is not only superior in formulation stability, It has excellent effect.

In addition, since the present invention maintains a gel form at room temperature, it is more convenient to apply the hemostatic agent to a bleeding site than a liquid or powdered hemostatic agent, and the convenience of use is improved.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. And the scope of the present invention should be understood as the scope of the following claims and their equivalents.

Claims (6)

Ferric sulfate, ferric subsulfate, aluminum sulfate, copper sulfate, aluminum chloride, zinc chloride, silver nitrate, and the like. A hemostatic component which is at least one selected from the group consisting of a mixture;
A solvent adapted to be mixed with the hemostatic component;
A first component for controlling viscosity, which is at least one selected from the group consisting of cellulose, cellulose derivatives, and mixtures thereof; And
And a viscosity-controlling second component which is mixed with the viscosity-controlling first component so as to adjust the viscosity thereof
Gel type animal hemostat composition. The method according to claim 1,
In the hemostatic composition for a gel type animal, the hemostatic component is 20 to 40 parts by weight, the solvent is 50 to 80 parts by weight, the viscosity-adjusting first component is 4 to 7 parts by weight per 66 parts by weight of the solvent, And the second component is provided in an amount of 6 to 9 parts by weight per 66 parts by weight of the solvent
Gel type animal hemostat composition. The method according to claim 1,
Wherein the cellulose derivative is at least one selected from the group consisting of carboxymethyl cellulose and hydroxyethyl cellulose
Gel type animal hemostat composition. The method according to claim 1,
The second component for viscosity control is at least one selected from the group consisting of butylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, and mixtures thereof Featured
Gel type animal hemostat composition. The method according to claim 1,
The hemostatic composition for a gel type animal further comprises 0.1 to 10 parts by weight of an antibacterial agent,
Wherein the antimicrobial agent is selected from the group consisting of povidone iodine, chloroxyrenol, lactoferrin, lysozyme, chitosan, nisin, and polylysine. Characterized in that it is any one of
Gel type animal hemostat composition. The method according to claim 1,
The viscosity of the hemostatic composition for a gel type animal is in the range of 1,000 to 30,000 cPs
Gel type animal hemostat composition.

Images